infections among patients receiving leukoreduced blood, compared with patients receiving buffy coat-depleted blood. 6 A second trial conducted by the same investigators designed to evaluate mortality documented a similar decrease in 30-day mortality in this same patient population. 7 These investigators postulated that depressed immunity following blood transfusions predisposed high-risk cardiovascular surgical patients to multiple organ failure and ultimately resulted in higher mortality. However, recent metaanalyses and reviews 8, 9 of the randomized trials do not provide convincing evidence for or against the potential role of leukoreduction in decreasing mortality or postoperative infections.
Given the current debate on the effectiveness of leukoreduction, 10 we conducted a large national study designed to determine the association of leukoreduction on rates of in-hospital death and serious nosocomial infection in a high-risk postoperative population receiving blood transfusions.
METHODS

Study Design
In this before-and-after retrospective cohort study, conducted from August 1998 to August 2000, we collected information on 14 786 postoperative patients from 23 Canadian academic and community hospitals representing all regions of the country. The study was designed to detect a clinically meaningful 20% relative decrease (1% absolute difference) in rates of in-hospital death and serious nosocomial infection.
Universal prestorage leukoreduction was regionally implemented across Canada between June and September 1999. Patients in the control period were admitted to the hospital in the period commencing 373 days prior to the date of implementation of leukoreduction and ending 7 days before this date. Patients in the intervention period were admitted to the hospital in the period commencing 60 days after the implementation date of universal prestorage leukoreduction. Both intervention and control cohorts consisted of 2 complete 1-year periods interrupted by a 67-day washout period, adopted to minimize contamination. This study was approved by the research ethics committees at all participating institutions and at the coordinating center.
Study Population
This study targeted surgical patient populations that consumed as much as 40% of the total blood supply 11 and who were considered at high risk of death or developing serious bacterial infections. 12 Based on these criteria, we enrolled all consecutive patients in 3 distinct high-risk categories: (1) patients following cardiovascular surgery requiring cardiopulmonary bypass; (2) patients requiring intraoperative repair of a hip fracture; and (3) postoperative and multiple trauma patients admitted to an intensive care unit. We excluded patients who were younger than 16 years; had a serious infection prior to receiving blood; had been previously included in this study; had no ongoing commitment to the provision of all necessary care because of a terminal illness or the patient's expressed wishes (eg, do-not-resuscitate order); were considered brain dead within the first 24 hours of hospital admission; did not survive 24 hours following the completion of the index surgical procedure or time of admission to the intensive care unit; received treatment for a hematologic malignancy in the past year or had undergone bone marrow transplantation; and who had received at least 1 blood transfusion in the year prior to the time of hospital admission.
Intervention and Outcomes
Canadian Blood Services and Héma Qué bec were the only agencies in Canada that collected, processed, and provided blood products to hospitals during this study. Donated blood was collected into CP2D anticoagulant solution and stored in 100 mL of Nutricel additive during this evaluation. 13, 14 Leukofiltration (Pall Medical, Blood Processing Group, East Hills, NY) using these systems reduced white blood cell content of a unit of red blood cells from an average of 3.0ϫ10 9 per unit to 2.5ϫ10 5 per unit, a decrease of 4 logs. Quality control measures were conducted by both blood services and the leukofilter manufacturer according to regulatory standards.
Both all-cause in-hospital deaths and confirmed serious nosocomial infections were considered to be primary outcomes. Serious nosocomial infections included pneumonia, bacteremia, and septic shock, as well as all surgical site infections (BOX). Outcomes must have occurred after the first blood transfusion and at least 2 days after the index procedure or intensive care unit admission. The diagnosis of confirmed nosocomial pneumonia was based on stringent criteria developed by Johanson et al 15 and Toews. 16 Bacteremia was defined as the identification of a recognized pathogen isolated from a blood culture specimen. The definition of septic shock required evidence of a systemic inflammatory response and hypotension that was unresponsive to fluid resuscitation and acute organ hypoperfusion manifested by lactic acidosis, oliguria, and confusion. [17] [18] [19] Surgical site infections included deep incision infections and organ or surgical site infections. 20, 21 For cardiac surgical procedures, we documented postsurgical major infections including mediastinitis, endocarditis, myocarditis, or pericarditis. Similarly, following intraoperative repair of hip fractures, we specifically sought to identify each episode of postoperative osteomyelitis, septic arthritis, or infected prosthesis. All organ system infections met US Centers for Disease Control and Prevention criteria. 17, [20] [21] [22] Secondary outcomes included an examination of item-specific criteria for all infections and each category of infection. We were also interested in the rates of fever, defined as a temperature exceeding 38.5°C and use of antibiotics for the treatment of serious infections. We also evaluated whether universal prestorage leukoreduction impacted the duration of organ support (respiratory support based on the num-THE CANADIAN UNIVERSAL LEUKOREDUCTION PROGRAM ber of days of mechanical ventilation, hemodynamic support based on the number of days requiring vasoactive drug, and renal support based on the number of days of dialysis dependence) as well as length of hospital and intensive care unit stay.
Data Collection
All data were abstracted from patient medical charts using standardized case report forms and detailed procedures manuals. Personnel performing data abstraction were given a dummy protocol aimed at masking the true intent of the project. All data collection was undertaken in concurrent prespecified monthly intervals in both 365-day observation periods to minimize potential information bias related to differential learning curves. To ensure data quality, all personnel completed a training session and participated in a quality assurance exercise in which data were abstracted from a standardized medical record. From this evaluation, we documented an overall accuracy rate exceeding 90% (97.5% for primary outcomes) compared with a criterion standard. In addition, experienced research personnel compared 10% of case report forms to the medical records. Once received by the coordinating center, all case report forms were manually reviewed for data quality and completeness. Each case report form was electronically scanned into a computerized TELEform database (Version 6.0, Cardiff Software Inc, Vista, Calif ) that included range and logic checks. Queries were sent to centers following all manual and electronic quality checks. A minimum set of data including hospital mortality and procedure was collected on all nontransfused patients during the same time period.
Statistical Analysis
We compared all major baseline variables before and after the implementation of the leukoreduction program with absolute differences and 95% confidence intervals (CIs). The effect of leukoreduction on the rates of inhospital mortality and all confirmed serious nosocomial infections were calculated using 2 statistics and unadjusted odds ratios (ORs) with 95% CIs. Mortality rates in nontransfused patients were also compared between time periods using the same statistical techniques.
Given the possibility of differences in patient characteristics and therapeutic interventions between treatment periods, logistic regression procedures were used to calculate adjusted ORs for rates of in-hospital mortality and serious nosocomial infections. Variable selection for the multivariate models involved a predefined 2-step process. First, we examined a series of variables known to be related to mortality and bacterial infections based on clinical or biological relevance within the following categories: demographic information (age, sex, and center), ma-
Box. Definitions for Serious Nosocomial Infections
Pneumonia
15,16
(1) New and progressive pulmonary infiltrate on sequential chest radiographs (2) Temperature Ͼ38°C (3) Total white blood cell count Ͼ12000 cells/mm 3 or Ͼ10% bands on differential cell count (4) Purulent tracheobronchial secretions (moderate numbers of organisms and polymorphonuclear cells with a few epithelial cells on microscopic examination of tracheal aspirate) A confirmed diagnosis of infection required all 4 criteria, while a suspected diagnosis did not require number 4.
Bacteremia/Severe Sepsis (1) Identification of a recognized pathogen isolated from a blood culture specimen. For commensal skin organisms, at least 2 positive blood cultures collected on separate occasions or venipuncture sites were required (2) Temperature Ͼ38°C or hypotension, defined as a systolic blood pressure either Ͻ90 mm Hg, or 40 mm Hg lower than baseline values
Septic Shock
17-19
(1) Systemic response to infection, including temperature Ͼ38°C or Ͻ36°C, heart rate Ͼ90/min, respiratory rate Ͼ20/min, CO 2 partial pressure Ͻ32 mm Hg, or an increased white blood cell count Ͼ12000 cells/mm 3 or Ͻ4000 cells/mm jor comorbid illnesses (14 major illnesses), medications used in the first 24 hours of care (13 major categories of medications), major disease categories (cardiac surgery, repair of hip fracture, or intensive care), previous transfusions (yes/no), and the number of blood transfusions (Յ3 vs Ͼ3). Second, any variable with an unequal distribution between treatment groups (Ͼ1% absolute difference) at baseline was added to the model. To understand the influence of each potential confounder on mortality, we also used a Mantel-Haenszel 2 analysis including the study intervention and each variable. The final model included age, sex, center, comorbid illness (severe lung disease), medications (aspirin, ␤-blockers, and angiotensin-converting enzyme inhibitors), major diseases, previous transfusion(s), and the total number of transfusions as well as the treatment period. To evaluate the influence of secular trends on hospital mortality, we plotted the adjusted ORs using the first period as the reference category for twelve 2-month intervals. Multivariate models using all variables except center also were generated within quartiles of numbers of units transfused (1 unit, 2 units, 3 to 4 units, and 5 units or more).
We used an identical approach to evaluate the impact of leukoreduction on secondary outcomes including fever and antibiotic use. As a secondary analysis, we compared the effect of leukoreduction on specific categories of infections. All infections were grouped into 3 clinically meaningful categories: pneumonia, bacteremia and septic shock, and surgical site infections (ie, all deep incision infections or organ space infections). Furthermore, several prespecified definitions were used to understand how various criteria affected inferences related to leukoreduction. In order of clinical significance, the definitions used were (1) confirmed infections for which all criteria were met; (2) suspected infections for which 1 criterion was not fulfilled; and (3) a physician's diagnosis of infection documented in the medical record. Secondary analyses also included an evaluation of fever episodes and the use of antibiotics for the prespecified serious infections. All secondary analyses used the same analytic plan and choice of variables in multivariate *One or more of the following comorbidities: acquired immunodeficiency syndrome, chronic renal failure, congestive heart failure, diabetes mellitus, disabling stroke, ischemic heart disease, metastatic cancer, obesity, severe cirrhosis or hepatic failure, severe dementia, severe immunodepression, severe lung disease, or other (eg, hypertension). †ASA score ranges from 1 to 5, where 1 represents good health and 5 moribund.
analyses as described in the analyses of primary outcomes.
Bivariate and multivariate procedures were used to compare all outcomes in the 3 predefined major disease subgroups of cardiac surgical disease, hip fracture repair, and critical care. Odds ratios and 95% CIs were reported for all outcomes. No adjustments were made for multiple comparisons. All analyses were conducted using SAS v8.0 (SAS Institute Inc, Cary, NC); PϽ.05 was set as statistical significance.
RESULTS
Patient Characteristics
During the study period a total of 14786 patients received red blood cell transfusions and met all eligibility criteria; 7804 patients received universal prestorage leukoreduced blood products while 6982 patients were enrolled in the control period. During this same time interval, there were 26183 patients who were not transfused: 12927 in the leukoreduction period and 13256 in the control period. All patients who met eligibility criteria identified through electronic search criteria at all participating institutions were included.
Overall, there were few important differences in baseline characteristics in transfused patients. Patients in the control period had a small but significant increase in the prevalence of severe lung disease. Patients who received leukoreduced blood were more likely to have been given aspirin, ␤-blockers, and angiotensin-converting enzyme inhibitors (TABLE 1) . No other important differences in baseline characteristics between treatment groups were identified. The average minimum hemoglobin concentration in patients receiving leukoreduced blood was statistically but not clinically less compared with controls (7. FIGURE 2 . By including the additional 106 patients who died within the first 48 hours as a sensitivity analysis, the adjusted OR was 0.88 (95% CI, 0.77-1.01; P=.06). There were no important changes in adjusted ORs when all 51 explanatory variables were sequentially added to multivariate models.
There was no clinically important or statistically significant decrease in confirmed infections associated with leukoreduction (unadjusted OR, 0.93; 95% CI, 0.84-1.04; P=. 20) . Following multivariate adjustment, the OR for confirmed infections was 0.97 (95% CI, 0.87-1.09; P =.63) (Figure 1 ). For suspected infections, leukoreduction was associated with a slight decrease in events (unadjusted OR, 0.91; 95% CI, 0.83-0.99; P=.05). This association did not remain significant after multivariate adjustment (adjusted OR, 0.94; 95% CI, 0.85-1.04; P=.21). Using the physician's diagnosis of infection as a definition, the unadjusted OR was 0.91 (95% CI, 0.83-0.99; P=.05) but the adjusted OR of 0.94 (95% CI, 0.85-1.05) was not significant (P=.27).There were no detectable differences in subtypes of infections or the 3 major clinical subgroups (PϾ.05 for all)
Secondary Outcomes
The proportion of patients with fever episodes decreased from 24.7% prior to the introduction of the leukoreduction program to 22.5% following its implementation (unadjusted OR, 0.88; 95% CI, 0.82-0.95; P=.001). This clinically important and statistically significant decrease in the odds of developing a fever persisted following multivariate adjustments (adjusted OR, 0.86; 95% CI, 0.79-0.94; PϽ.001). The use of antibiotics also decreased following leukoreduction. The crude OR was 0.89 (95% CI, 0.81-0.97; P=.01) while the adjusted OR was 0.90 (95% CI, 0.82 to 0.99; P=.03). The decreases in the frequency of patients experiencing at least 1 episode of fever and in the use of antibiotics for serious infections were comparable in the major subgroups (Table 2 and TABLE 3 ). See Table 2 footnote for list of covariates adjusted for. CI indicates confidence interval; OR, odds ratio. Bulk of washout occurred during June/July 1999, but some patients at some centers went through washout before or after these months. CI indicates confidence interval; OR, odds ratio.
In terms of other secondary outcomes, there were no major differences in average hospital length of stay (16.6 [16.7] 
COMMENT
In this study, we documented a decrease in mortality associated with the implementation of universal leukore- duction without observed changes in serious infections. We also noted an important decrease in the proportion of patients experiencing at least 1 fever episode as well as an associated reduction in the use of antibiotics. Therefore, the filtration of leukocytes from donated blood appeared to be associated with important health benefits.
This before-and-after study was designed to detect an absolute decrease in both mortality and serious nosocomial infections in the range of 1%. 8, 9 We reasoned that such small differences would be important, given that the results impact high-risk patients who collectively require a large portion of the blood supply and given that there are few adverse consequences other than cost. Indeed, assuming a 7% mortality rate in the control period, the decreased odds of death generated from this study would translate into 1 life saved for every 120 patients who receive leukoreduced blood, a number needed to be treated in the same order of magnitude as recent cardiovascular trials. 23 The observed improvement in mortality also was consistent among all subgroups and throughout a range of exposures to blood. These findings persisted after multivariate analysis, through a number of sensitivity analyses and demonstrated appropriate time trends. Our observations related to mortality and infections were similar to 2 studies in high-risk cardiac surgery conducted by van de Watering et al 6 and Bilgin et al. 7 The other studies documented an important absolute decrease in mortality between 4% and 5% in the 2 trials without consistent decreases in infections. The smaller difference in mortality rates noted in our study may be attributed to a more heterogeneous population of patients who may have received less blood.
Several recent studies concluded that leukoreduction did not affect major clinical outcomes. 24, 25 In comparing 2780 patients receiving nonleukoreduced vs leukoreduced blood products, Dzik and colleagues 24 noted comparable in-hospital mortality rates (8.5% vs 9.0%, respectively; P=.64) but fewer fever episodes (0.77% vs 0.22%, respectively; P = .06). In contrast, we observed a decrease in mortality and in the use of antibiotics that may be explained by our selection of higher-risk patients compared with all hospitalized patients requiring a transfusion.
Our results suggest that the observed decrease in the number of deaths may not have been mediated through immune suppression and increased rates of serious infections. An alternative explanation is that transfused leukocytes result in a proinflammatory microvascular effect leading to important clinical consequences. [26] [27] [28] [29] Given that rates of confirmed serious infections were not affected by the implementation of the leukoreduction program, the decrease in fever episodes may be predominantly related to a decrease in febrile nonhemolytic reactions. Physicians appear to have responded to lowered rates of fever by prescribing fewer antibiotics. Therefore, fever episodes in potentially unstable patients may result in lower costs of care.
Because the implementation of a universal leukoreduction program in Canada was mandated by the regulatory agency, the optimal experimental design was a before-and-after study. We took every precaution in our study to minimize the influence of information and selection biases, including objective outcomes, masking of data abstraction personnel, and standardized data collection procedures. 30 To ensure generalizability and to minimize the impact of secular trends, we selected patients undergoing several different high-risk procedures and enrolled patients from both community and academic centers. We noted few important differences in baseline characteristics or therapeutic interventions administered in the first 24 hours of acute care among patients treated in the control and leukoreduction periods. Differences at baseline, when detected, either had no effect on outcomes or shifted the OR toward the null. Despite careful attention to potential biases, our results may have been affected by secular trends and incomplete information.
Universal prestorage leukoreduction was associated with decreased mortality, number of fever episodes, and subsequent use of antibiotics in highrisk patients. The mechanism leading to these potential health benefits did not appear related to decreased infections. Although this study adds to the literature in support of the adoption of universal leukoreduction, additional data from clinical trials are needed to provide evidence for the efficacy of leukoreduction of red blood cell transfusions.
